Genmab — Juli 2018
-
Og så kan det vel berolig forum, at pollux vil have pfs på over 40 måneder, mens pfs i første linies kontrolarm forventeligt vil ligge omkring de 30 måneder
-
Ongoing Trials Offer Potential for Second-Generation Therapies as Standard-of-Care in Myeloma https://www.journalofclinicalpathways.com/news/ongoing-trials-offer-potential-second-generation-therapies-standard-care-myeloma
-
repeating this as it also had some MAIA discussion / Extrapolating from Clinical Trials: Daratumumab in MM / https://www.onclive.com/peer-exchange/myeloma-next-gen-regimens/extrapolating-from-clinical-trials-daratumumab-in-mm
-
Er det ikke lidt risky at købe nu hvor først 1120 og derefter 1100 er brudt nedad?
-
De kan sagtens fortsætte nogle dage
endnu med at presse den nedad -
the spanish SELIBORDARA trial started recruiting fast https://clinicaltrials.gov/ct2/history/NCT03589222?A=1&B=2&C=merged
-
Vedr. DuoBody-CDxCD (B-cell malignancies). På Genmab’s hjemmeside har der hidtil været en bemærkning om at den første patient endnu ikke er doseret. Denne bemærkning er fjernet, hvilket i så fald må betyde at studiet nu endelig er startet!
Er der nogen der kan se hvor/hvornår m.v. studiet er igangsat? -
Det er godt nok en grim omgang i dag led de anonyme i ledtog med Nordea.
-
Håber ikke der er nogle som har fået nyheder før os andre!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind